Drug Trial Radar · NCT01175356
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
99
Actual
Start
Dec 21, 2011
Primary completion
Sep 28, 2016
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Aug 4, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot clinical trial studies induction therapy followed by iobenguane I 131 and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and maintenance therapy with isotretinoin. Radioisotope therapy, such as iobenguane I 131, releases radiation that kills tumor cells. Drugs used in chemotherapy, such as carboplatin, etoposide phosphate, busulfan, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that are destroyed by iobenguane I 131 and chemotherapy. Giving radioisotope therapy, chemotherapy, and peripheral stem cell transplant may kill more tumor cells.
Conditions
- Ganglioneuroblastoma
- Localized Resectable Neuroblastoma
- Localized Unresectable Neuroblastoma
- Regional Neuroblastoma
- Stage 4 Neuroblastoma
- Stage 4S Neuroblastoma
Interventions
3-Dimensional Conformal Radiation TherapyRadiation
Undergo radiotherapy
Autologous Hematopoietic Stem Cell TransplantationProcedure
Undergo autologous in vitro-treated peripheral blood stem cell transplantation
BusulfanDrug
Given IV
CisplatinDrug
Given IV
CyclophosphamideDrug
Given IV
Doxorubicin HydrochlorideDrug
Given IV
Etoposide PhosphateDrug
Given IV
External Beam Radiation TherapyRadiation
Undergo radiotherapy
In Vitro-Treated Peripheral Blood Stem Cell TransplantationProcedure
Undergo autologous in vitro-treated peripheral blood stem cell transplantation
Intensity-Modulated Radiation TherapyRadiation
Undergo radiotherapy
Iobenguane I-131Radiation
Given IV
IsotretinoinDrug
Given PO
Laboratory Biomarker AnalysisOther
Correlative studies
MelphalanDrug
Given IV
Pharmacological StudyOther
Correlative studies
Questionnaire AdministrationOther
Ancillary studies
Therapeutic Conventional SurgeryProcedure
Undergo surgery
Topotecan HydrochlorideDrug
Given IV
Vincristine SulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131Time frame: Up to 6 weeks after course 5 of induction
- Percentage of MIBG Avid Patients Treated With MIBG Labeled With Iodine-131 and Bu/Mel ChemotherapyTime frame: Up to day -6 of conditioning
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Phoenix Childrens Hospital
Phoenix, Arizona
Children's Hospital Los Angeles
Los Angeles, California
UCSF Medical Center-Parnassus
San Francisco, California
UCSF Medical Center-Mission Bay
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Children's National Medical Center
Washington D.C., District of Columbia
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia
University of Chicago Comprehensive Cancer Center
Chicago, Illinois
Dana-Farber Cancer Institute
Boston, Massachusetts
C S Mott Children's Hospital
Ann Arbor, Michigan
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas
Cook Children's Medical Center
Fort Worth, Texas
Primary Children's Hospital
Salt Lake City, Utah
Seattle Children's Hospital
Seattle, Washington
Providence Sacred Heart Medical Center and Children's Hospital
Spokane, Washington
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin
Children's Hospital of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.